Active Stock Alerts: Protalix BioTherapeutics, Chemtura, Broadcom, Wynn, Herbalife May 2nd
Protalix BioTherapeutics, Inc. (AMEX:PLX): Oppenheimer increased its target on Protalix after the FDA approved the company’s Gaucher disease treatment, Elelyso. The firm recommends buying the stock on strength.
Chemtura Corp. Common Stock (NYSE:CHMT): Oppenheimer raised its target on Chemtura after the company reported stronger than expected Q1 results, and provided guidance that the firm views as positive. The firm thinks that the stock can reach the $60s range in 2016, and it maintains an Outperform rating.
Broadcom Corp. (NASDAQ:BRCM): After Broadcom reported stronger than expected Q1 results, DA Davidson expects the company to have strong baseband and combo product sales in 2H12. The firm thinks that the company has several upcoming positive catalysts, and it reiterates a Buy rating on the shares.
Wynn Resorts Ltd. (NASDAQ:WYNN): Morgan Stanley believes Wynn Resorts could be up 5%-10% on the formal gazette approval for Cotai development. The firm include $13 per share for Wynn Cotai in its valuation. Shares are Equal Weight rated.
Herbalife Ltd. (NYSE:HLF): After Herbalife tumbled 20% after short-seller David Einhorn raised a couple of questions about the company, DA Davidson says that the questions were “basic,” and it is still bullish on the stock. The firm believes that the company reported excellent results, and it maintains a Buy rating.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.